MEDICAL DEVICE NEWS MAGAZINE

Friday, September 30, 2022

MEDICAL DEVICE NEWS MAGAZINE

|

Contact us 561.316.3330

Abbott Receives Expanded Indication From the U.S. FDA for Directional Deep Brain Stimulation System to Treat Parkinson’s Disease

Abbott has announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication for the company’s Infinity™ Deep Brain Stimulation (DBS) system to include targeting of an area of the brain called the internal globus pallidus (GPi).

Abbott notes the GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson’s disease not adequately controlled by medication.

With this approval, Abbott’s Infinity DBS is now the only directional DBS system approved for all major targets used to treat movement disorders, Parkinson’s disease and Essential Tremor: the subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi.  It is the world’s first and only DBS system operating in these indications on an iOS software platform with Bluetooth® wireless technology. Clinicians can streamline the programming process with an iPad mini device using Abbott’s new Informity™ Programming feature to become more efficient in their practice and achieve optimal outcomes with directional leads. Patients can discreetly manage their symptoms with their Infinity DBS System iPod touch controller.

“The internal segment of the global pallidus, or GPi, is a well-established valuable DBS target for the management of the motor signs associated with Parkinson’s disease, and is a preferred target for many patients, particularly for those with troublesome medication induced dyskinesia,” said Jerrold Vitek, M.D., Ph.D., head of the Neurology Department, director of the Neuromodulation Research Program, and center director of the University of Minnesota Udall Center of Excellence for Parkinson’s Research. “This approval expands the options for patients to tailor treatment to their unique needs, with the added benefits of being able to target precise areas and utilizing a patient-friendly iOS device.”

Abbott’s Infinity DBS system with directional leads provides directed stimulation to areas of the brain to optimize patient outcomes and limit side effects. The platform’s future-ready technology has the ability to seamlessly upgrade the approved capabilities and new therapy features of the Infinity DBS system through simple, over-the-air updates.

Abbott continues to advance its Infinity DBS system with a focus on personalized and patient-centric innovations for people with movement disorders, supported by data from the PROGRESS study – the largest DBS study for directional lead use in Parkinson’s disease.

“Abbott’s PROGRESS study has led the way in establishing the value of directional DBS systems for targeted areas of the brain,” noted Binith Cheeran, M.D., director of medical affairs, deep brain stimulation, a part of Abbott’s neuromodulation business. “The approval of Abbott’s Infinity DBS system with targeted stimulation is a significant advancement for people living with Parkinson’s disease and their care teams. The ability to optimize the programming for each individual opens the door for a new standard of care for DBS therapy.”

Data indicates that patients gravitate toward medical devices that are intuitive and low maintenance, such as the Infinity DBS system’s dual channel recharge-free device.ii The development of Abbott’s neuromodulation portfolio is focused on the patient’s therapeutic experience, coupled with the science, data and patient input to drive innovation that helps people suffering from movement disorders feel as normal as possible.

Abbott’s Infinity DBS system also has CE Mark and is available in nearly 30 countries.

(For U.S. important safety information, visit here.)


References:

i Parkinson’s Foundation 
ii Khaleeq T., Hasegawa H., Samuel M., Ashkan K. 2018. Fixed-Life or Rechargeable Battery for Deep Brain
Stimulation: Which Do Patients Prefer? Neuromodulation 2018; E-pub ahead of print. DOI:10.1111/ner.12810

SourceAbbott
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
spot_img
spot_img

Our Sister Publication

Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy